ABSTRACT
Naturally occurring compounds such as sesquiterpenes and sesquiterpenoids (SQTs) have been shown to modulate GABAA receptors (GABAA Rs). In this study, the modulatory potential of 11 SQTs at GABAA Rs was analyzed to characterize their potential neurotropic activity. Transfected HEK293 cells and primary hippocampal neurons were functionally investigated using electrophysiological whole-cell recordings. Significantly different effects of ß-caryophyllene and α-humulene, as well as their respective derivatives ß-caryolanol and humulol, were observed in the HEK293 cell system. In neurons, the concomitant presence of phasic and tonic GABAA R configurations accounts for differences in receptor modulation by SQTs. The in vivo presence of the γ2 and δ subunits is important for SQT modulation. While phasic GABAA receptors in hippocampal neurons exhibited significantly altered GABA-evoked current amplitudes in the presence of humulol and guaiol, negative allosteric potential at recombinantly expressed α1 ß2 γ2 receptors was only verified for humolol. Modeling and docking studies provided support for the binding of SQTs to the neurosteroid-binding site of the GABAA R localized between transmembrane segments 1 and 3 at the (+ α)-(- α) interface. In sum, differences in the modulation of GABAA R isoforms between SQTs were identified. Another finding is that our results provide an indication that nutritional digestion affects the neurotropic potential of natural compounds.
Subject(s)
GABA-A Receptor Antagonists/pharmacology , Molecular Docking Simulation/methods , Plant Extracts/pharmacology , Receptors, GABA-A/physiology , Sesquiterpenes/pharmacology , Allosteric Regulation/drug effects , Allosteric Regulation/physiology , Animals , Female , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/isolation & purification , HEK293 Cells , Humans , Mice , Neurons/drug effects , Neurons/physiology , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Pregnancy , Receptors, GABA-A/chemistry , Sesquiterpenes/chemistry , Sesquiterpenes/isolation & purificationABSTRACT
BACKGROUND: Central nervous system disorders such as anxiety, depression and epilepsy are characterized by sharing several molecular mechanisms in common and the involvement of the L-arginine/NO pathway in neurobehavioral studies with ß-caryophyllene is still little discussed. OBJECTIVES: One of the objectives of the present study was to demonstrate the anxiolytic behavioral effect of ß-caryophyllene (ß-CBP) in female Swiss mice, as well as to investigate the molecular mechanisms underlying the results obtained. METHODS: This study evaluated the neurobehavioral effects of ß-CBP using the open field test, rota- rod test, elevated plus maze test, novelty suppressed feeding test, tail suspension test and forced swim test, as well as pilocarpine, pentylenetetrazole and isoniazid-induced epileptic seizure models. RESULTS: The results demonstrated that the neuropharmacological activities of ß-CBP may involve benzodiazepine/GABAergic receptors, since the pre-treatment of ß-CBP (200 mg/kg) associated with flumazenil (5 mg/kg, benzodiazepine receptor antagonist) and bicuculline (1 mg/kg, selective GABAA receptor antagonist) reestablished the anxiety parameters in the elevated plus-maze test, as well as the results of reduced latency to consume food in the novelty suppressed feeding test. In addition to benzodiazepine/GABAergic receptors, the neuropharmacological properties of ß-CBP may be related to inhibition of nitric oxide synthesis, since pre-treatment with L-arginine (500-750 mg/kg) reversed significantly the anxiolytic, antidepressant and anticonvulsant activities of ß-CBP. CONCLUSION: The results obtained provide additional support in understanding the neuromolecular mechanisms underlying the anxiolytic, antidepressant and anticonvulsive properties of ß-CBP in female Swiss mice.
Subject(s)
Anti-Anxiety Agents/chemistry , Anticonvulsants/chemistry , Antidepressive Agents/chemistry , GABA-A Receptor Antagonists/chemistry , Polycyclic Sesquiterpenes/chemistry , Animals , Anti-Anxiety Agents/pharmacology , Anticonvulsants/pharmacology , Antidepressive Agents/pharmacology , Arginine , Behavior, Animal , Benzodiazepines/metabolism , Bicuculline/chemistry , Bicuculline/pharmacology , Female , Flumazenil/chemistry , Flumazenil/pharmacology , GABA-A Receptor Antagonists/pharmacology , Humans , Maze Learning , Mice , Nitric Oxide/metabolism , Polycyclic Sesquiterpenes/pharmacology , Receptors, GABA-A/metabolism , Seizures/chemically induced , Signal TransductionABSTRACT
Most general anaesthetics and classical benzodiazepine drugs act through positive modulation of γ-aminobutyric acid type A (GABAA) receptors to dampen neuronal activity in the brain1-5. However, direct structural information on the mechanisms of general anaesthetics at their physiological receptor sites is lacking. Here we present cryo-electron microscopy structures of GABAA receptors bound to intravenous anaesthetics, benzodiazepines and inhibitory modulators. These structures were solved in a lipidic environment and are complemented by electrophysiology and molecular dynamics simulations. Structures of GABAA receptors in complex with the anaesthetics phenobarbital, etomidate and propofol reveal both distinct and common transmembrane binding sites, which are shared in part by the benzodiazepine drug diazepam. Structures in which GABAA receptors are bound by benzodiazepine-site ligands identify an additional membrane binding site for diazepam and suggest an allosteric mechanism for anaesthetic reversal by flumazenil. This study provides a foundation for understanding how pharmacologically diverse and clinically essential drugs act through overlapping and distinct mechanisms to potentiate inhibitory signalling in the brain.
Subject(s)
Anesthetics, General/chemistry , Anesthetics, General/pharmacology , Barbiturates/chemistry , Barbiturates/pharmacology , Benzodiazepines/chemistry , Benzodiazepines/pharmacology , Cryoelectron Microscopy , Receptors, GABA-A/chemistry , Allosteric Regulation/drug effects , Anesthetics, General/metabolism , Barbiturates/metabolism , Benzodiazepines/metabolism , Bicuculline/chemistry , Bicuculline/metabolism , Bicuculline/pharmacology , Binding Sites , Binding, Competitive/drug effects , Diazepam/chemistry , Diazepam/metabolism , Diazepam/pharmacology , Electrophysiology , Etomidate/chemistry , Etomidate/metabolism , Etomidate/pharmacology , Flumazenil/pharmacology , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/metabolism , GABA-A Receptor Antagonists/pharmacology , Humans , Ligands , Models, Molecular , Molecular Conformation , Molecular Dynamics Simulation , Phenobarbital/chemistry , Phenobarbital/metabolism , Phenobarbital/pharmacology , Picrotoxin/chemistry , Picrotoxin/metabolism , Picrotoxin/pharmacology , Propofol/chemistry , Propofol/metabolism , Propofol/pharmacology , Receptors, GABA-A/metabolism , Receptors, GABA-A/ultrastructure , gamma-Aminobutyric Acid/chemistry , gamma-Aminobutyric Acid/metabolism , gamma-Aminobutyric Acid/pharmacologyABSTRACT
Here we interrogate the structurally dense (1.64 mcbits/Å3) GABAA receptor antagonist bilobalide, intermediates en route to its synthesis, and related mechanistic questions. 13C isotope labeling identifies an unexpected bromine migration en route to an α-selective, catalytic asymmetric Reformatsky reaction, ruling out an asymmetric allylation pathway. Experiment and computation converge on the driving forces behind two surprising observations. First, an oxetane acetal persists in concentrated mineral acid (1.5 M DCl in THF-d8/D2O); its longevity is correlated to destabilizing steric clash between substituents upon ring-opening. Second, a regioselective oxidation of des-hydroxybilobalide is found to rely on lactone acidification through lone-pair delocalization, which leads to extremely rapid intermolecular enolate equilibration. We also establish equivalent effects of (-)-bilobalide and the nonconvulsive sesquiterpene (-)-jiadifenolide on action potential-independent inhibitory currents at GABAergic synapses, using (+)-bilobalide as a negative control. The high information density of bilobalide distinguishes it from other scaffolds and may characterize natural product (NP) space more generally. Therefore, we also include a Python script to quickly (ca. 132â¯000 molecules/min) calculate information content (Böttcher scores), which may prove helpful to identify important features of NP space.
Subject(s)
Cyclopentanes/chemistry , Furans/chemistry , GABA-A Receptor Antagonists/chemical synthesis , Ginkgo biloba/chemistry , Ginkgolides/chemistry , Bromides/chemistry , Cyclopentanes/chemical synthesis , Furans/chemical synthesis , GABA-A Receptor Antagonists/chemistry , Ginkgo biloba/metabolism , Ginkgolides/chemical synthesis , Isotope Labeling , Lactones/chemistry , Molecular Conformation , Oxidation-Reduction , StereoisomerismABSTRACT
The inhibition of GABAA can be used in general anesthesia. Although, barbiturates and thiobarbiturates are used in anesthesia, the mechanism of their action hasn't been established. QSAR modeling is a wieldy used technique in these cases and this study presents the QSAR modeling for a group of barbiturates and thiobarbiturates with determined anesthetic activity. Developed QSAR models were based on conformation independent and 2D descriptors as well as field contribution. As descriptors used for developing conformation independent QSAR models, (SMILES) notation and local invariants of the molecular graph were used. Monte Carlo optimization method was applied for building QSAR models for two defined activities. Methodology for developing QSAR models capable of dealing with the small dataset that integrates dataset curation, "exhaustive" double cross-validation and a set of optimal model selection techniques including consensus predictions was used. Two-dimensional descriptors with definite physicochemical meaning were used and modeling was done with the application of both partial least squares and multiple linear regression models with three latent variables related to simple and interpretable 2D descriptors. Different statistical methods, including novel method - the index of ideality of correlation, were used to test the quality of the developed models, especially robustness and predictability and all obtained results were good. In this study, obtained results indicate that there is a very good correlation between all developed models. Molecular fragments that account for the increase/decrease of a studied activity were defined and further used for the computer-aided design of new compounds as potential anesthetics.
Subject(s)
Anesthetics/pharmacology , Barbiturates/pharmacology , GABA-A Receptor Antagonists/pharmacology , Quantitative Structure-Activity Relationship , Receptors, GABA-A/metabolism , Thiobarbiturates/pharmacology , Anesthetics/chemistry , Barbiturates/chemistry , GABA-A Receptor Antagonists/chemistry , Humans , Models, Molecular , Molecular Structure , Thiobarbiturates/chemistryABSTRACT
γ-aminobutyric acid type-A receptors (GABAARs) are inhibitory ligand-gated ion channels in the brain that are crucial for controlling neuronal excitation. To explore their physiological roles in cellular and neural network activity, it is important to understand why specific GABAAR isoforms are distributed not only to various brain regions and cell types, but also to specific areas of the membrane in individual neurons. To address this aim we have developed a novel photosensitive compound, azogabazine, that targets and reversibly inhibits GABAARs. The receptor selectivity of the compound is based on the competitive antagonist, gabazine, and photosensitivity is conferred by a photoisomerisable azobenzene group. Azogabazine can exist in either cis or trans conformations that are controlled by UV and blue light respectively, to affect receptor inhibition. We report that the trans-isomer preferentially binds and inhibits GABAAR function, whilst promotion of the cis-isomer caused unbinding of azogabazine from GABAARs. Using cultured cerebellar granule cells, azogabazine in conjunction with UV light applied to defined membrane domains, revealed higher densities of GABAARs at somatic inhibitory synapses compared to those populating proximal dendritic zones, even though the latter displayed a higher number of synapses per unit area of membrane. Azogabazine also revealed more pronounced GABA-mediated inhibition of action potential firing in proximal dendrites compared to the soma. Overall, azogabazine is a valuable addition to the photochemical toolkit that can be used to interrogate GABAAR function and inhibition.
Subject(s)
Dendrites/metabolism , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/metabolism , Optogenetics/methods , Receptors, GABA-A/chemistry , Receptors, GABA-A/metabolism , Animals , Animals, Newborn , Cells, Cultured , Cerebellum/drug effects , Cerebellum/metabolism , Dendrites/drug effects , Dose-Response Relationship, Drug , GABA-A Receptor Antagonists/pharmacology , HEK293 Cells , Humans , Inhibitory Postsynaptic Potentials/drug effects , Inhibitory Postsynaptic Potentials/physiology , Protein Binding/physiology , Rats , Rats, Sprague-DawleyABSTRACT
Many allosteric binding sites that modulate gamma aminobutyric acid (GABA) effects have been described in heteropentameric GABA type A (GABAA) receptors, among them sites for benzodiazepines, pyrazoloquinolinones and etomidate. Diazepam not only binds at the high affinity extracellular "canonical" site, but also at sites in the transmembrane domain. Many ligands of the benzodiazepine binding site interact also with homologous sites in the extracellular domain, among them the pyrazoloquinolinones that exert modulation at extracellular α+/ß- sites. Additional interaction of this chemotype with the sites for etomidate has also been described. We have recently described a new indole-based scaffold with pharmacophore features highly similar to pyrazoloquinolinones as a novel class of GABAA receptor modulators. Contrary to what the pharmacophore overlap suggests, the ligand presented here behaves very differently from the identically substituted pyrazoloquinolinone. Structural evidence demonstrates that small changes in pharmacophore features can induce radical changes in ligand binding properties. Analysis of published data reveals that many chemotypes display a strong tendency to interact promiscuously with binding sites in the transmembrane domain and others in the extracellular domain of the same receptor. Further structural investigations of this phenomenon should enable a more targeted path to less promiscuous ligands, potentially reducing side effect liabilities.
Subject(s)
GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Protein Domains/drug effects , Receptors, GABA-A/metabolism , Allosteric Regulation/drug effects , Animals , Benzodiazepines/chemistry , Benzodiazepines/pharmacology , Binding Sites/drug effects , Drug Design , Humans , Ligands , Models, Molecular , Quinolones/chemistry , Quinolones/pharmacology , Receptors, GABA-A/chemistry , gamma-Aminobutyric Acid/metabolismABSTRACT
The biologically active alkaloid muscimol is present in fly agaric mushroom (Amanita muscaria), and its structure and action is related to human neurotransmitter γ -aminobutyric acid (GABA). The current study reports on determination of muscimol form present in water solution using multinuclear 1 H and 13 C nuclear magnetic resonance (NMR) experiments supported by density functional theory molecular modeling. The structures of three forms of free muscimol molecule both in the gas phase and in the presence of water solvent, modeled by polarized continuous model, and nuclear magnetic isotropic shieldings, the corresponding chemical shifts, and indirect spin-spin coupling constants were calculated. Several J-couplings observed in proton and carbon NMR spectra, not available before, are reported. The obtained experimental spectra, supported by theoretical calculations, favor the zwitterion form of muscimol in water. This structure differs from NH isomer, previously determined in dimethyl sulfoxide (DMSO) solution. In addition, positions of signals C3 and C5 are reversed in both solvents.
Subject(s)
Amanita/chemistry , GABA-A Receptor Antagonists/chemistry , Muscimol/chemistry , Water/chemistry , Carbon Isotopes , Density Functional Theory , GABA-A Receptor Antagonists/isolation & purification , GABA-A Receptor Antagonists/pharmacology , Humans , Magnetic Resonance Spectroscopy , Models, Molecular , Muscimol/isolation & purification , Muscimol/pharmacology , Protons , Receptors, GABA/metabolismABSTRACT
The ionotropic GABAA receptors represent the main target for different groups of widely used drugs having hypnotic and anxiolytic effects. So far, most approaches used to assess GABA activity involve invasive low -throughput electrophysiological techniques or rely on fluorescent dyes, preventing the ability to conduct noninvasive and thus nonperturbing screens. To address this limitation, we have developed an automated marker-free cell imaging method, based on digital holographic microscopy (DHM). This technology allows the automatically screening of compounds in multiple plates without having to label the cells or use special plates. This methodological approach was first validated by screening the GABAA receptor expressed in HEK cells using a selection of active compounds in agonist, antagonist, and modulator modes. Then, in a second blind screen of a library of 3041 compounds (mostly composed of natural products), 5 compounds having a specific agonist action on the GABAA receptor were identified. The hits validated from this unbiased screen were the natural products muscimol, neurosteroid alphaxalone, and three compounds belonging to the avermectin family, all known for having an agonistic effect on the GABAA receptor. The results obtained were exempt from false negatives (structurally similar unassigned hits), and false-positive hits were detected and discarded without the need for performing electrophysiological measurements. The outcome of the screen demonstrates the applicability of our screening by imaging method for the discovery of new chemical structures, particularly regarding chemicals interacting with the ionotropic GABAA receptor and more generally with any ligand-gated ion channels and transporters.
Subject(s)
GABA-A Receptor Agonists/isolation & purification , GABA-A Receptor Antagonists/isolation & purification , Molecular Imaging/methods , Receptors, GABA-A/genetics , Biological Products/chemistry , Biological Products/isolation & purification , Electrophysiological Phenomena , GABA-A Receptor Agonists/chemistry , GABA-A Receptor Antagonists/chemistry , High-Throughput Screening Assays/methods , Holography , Humans , Image Processing, Computer-Assisted/methods , Microscopy , gamma-Aminobutyric Acid/genetics , gamma-Aminobutyric Acid/metabolismABSTRACT
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter within the central nervous system (CNS) with fast, transsynaptic, and modulatory extrasynaptic effects being mediated by the ionotropic GABA type A receptors (GABAARs). These receptors are of particular interest because they are the molecular target of a number of pharmacological agents, of which the benzodiazepines (BZDs), such as diazepam, are the best described. The anxiolytic, sedating, and myorelaxant effects of BZDs are mediated by separate populations of GABAARs containing either α1, α2, α3, or α5 subunits and the molecular dissection of the pharmacology of BZDs indicates that subtype-selective GABAAR modulators will have novel pharmacological profiles. This is best exemplified by α2/α3-GABAAR positive allosteric modulators (PAMs) and α5-GABAAR negative allosteric modulators (NAMs), which were originally developed as nonsedating anxiolytics and cognition enhancers, respectively. This review aims to summarize the current state of the field of subtype-selective GABAAR modulators acting via the BZD binding site and their potential clinical indications.
Subject(s)
GABA Modulators/therapeutic use , GABA-A Receptor Agonists/therapeutic use , GABA-A Receptor Antagonists/therapeutic use , Receptors, GABA-A/metabolism , Animals , Binding Sites , GABA Modulators/chemistry , GABA Modulators/pharmacology , GABA-A Receptor Agonists/chemistry , GABA-A Receptor Agonists/pharmacology , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Humans , Molecular Structure , Protein Subunits/metabolism , Receptors, GABA-A/chemistryABSTRACT
A novel series of 1,2,3-triazolo-benzodiazepine derivatives 6a-o has been synthesized and evaluated in vivo for their anticonvulsant activities using by pentylenetetrazole (PTZ)- and maximal electroshock (MES)-induced seizures in mice. The synthetic approach started with diazotizing 2-aminobenzoic acids 1 to produce 2-azidobenzoic acids 2. Next, reaction of the latter compounds with propargylamine 3, benzaldehyde 4, and isocyanides 5 led to the formation of the title compounds 6a-o, in good yields. All the synthesized compounds exhibited high anticonvulsant activity in the PTZ test, comparable to or better than the standard drug diazepam. Among the tested compounds, N-(tert-butyl)-2-(9-chloro-6-oxo-4H-[1,2,3]triazolo[1,5-a][1,4]benzodiazepin-5(6H)-yl)-2-(3-bromophenyl)acetamide 6h was the most potent compound in this assay. Moreover, compounds 6i and 6k showed excellent activity in MES test. Loss of the anticonvulsant effect of compound 6h in the presence of flumazenil in the PTZ test and appropriate interaction of this compound in the active site of benzodiazepine (BZD)-binding site of GABAA receptor confirm involvement of BZD receptors in the anticonvulsant activity of compound 6h. A novel series of 1,2,3-triazolo-benzodiazepine derivatives 6a-o have been synthesized and evaluated in vivo for their anticonvulsant activities using by pentylenetetrazole (PTZ)- and maximal electroshock (MES)-induced seizures in mice. All the synthesized compounds exhibited high anticonvulsant activity, comparable to or better than the standard drug diazepam in the PTZ test and compounds 6i and 6k showed excellent activity in MES test. Flumazenil test and in silico docking study confirm involvement of benzodiazepine receptors in the anticonvulsant activity of these compounds.
Subject(s)
Anticonvulsants/chemistry , Anticonvulsants/pharmacology , Benzodiazepines/chemistry , Benzodiazepines/pharmacology , Triazoles/chemistry , Anticonvulsants/chemical synthesis , Benzodiazepines/chemical synthesis , Binding Sites , Chemistry Techniques, Synthetic , Drug Design , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Molecular Docking Simulation , Molecular Dynamics Simulation , Molecular Structure , Protein Binding , Quantitative Structure-Activity Relationship , Receptors, GABA-A/chemistry , Seizures/drug therapy , Seizures/etiologyABSTRACT
The nicotinic acetylcholine receptor (nAChR) is an excitatory pentameric ligand-gated ion channel (pLGIC), homologous to the inhibitory γ-aminobutyric acid (GABA) type A receptor targeted by pharmaceuticals and endogenous sedatives. Activation of the GABAA receptor by the neurosteroid allopregnanolone can be inhibited competitively by thyroid hormone (L-3,3',5-triiodothyronine, or T3), but modulation of nAChR by T3 or neurosteroids has not been investigated. Here we show that allopregnanolone inhibits the nAChR from Torpedo californica at micromolar concentrations, as do T3 and the anionic neurosteroid pregnenolone sulfate (PS). We test for the role of protein and ligand charge in mediated receptor inhibition by varying pH in a narrow range around physiological pH. We find that both T3 and PS become less potent with increasing pH, with remarkably similar trends in IC50 when T3 is neutral at pH < 7.3. After deprotonation of T3 (but no additional deprotonation of PS) at pH 7.3, T3 loses potency more slowly with increasing pH than PS. We interpret this result as indicating the negative charge is not required for inhibition but does increase activity. Finally, we show that both T3 and PS affect nAChR channel desensitization, which may implicate a binding site homologous to one that was recently indicated for accelerated desensitization of the GABAA receptor by PS.
Subject(s)
Nicotinic Antagonists/pharmacology , Pregnenolone/pharmacology , Receptors, Nicotinic/metabolism , Torpedo/metabolism , Triiodothyronine/pharmacology , Animals , Dose-Response Relationship, Drug , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Inhibitory Concentration 50 , Kinetics , Molecular Structure , Nicotinic Antagonists/chemistry , Oocytes/metabolism , Pregnenolone/chemistry , Receptors, GABA-A/metabolism , Triiodothyronine/chemistryABSTRACT
We previously published a series of 8-methoxypirazolo[1,5-a]quinazolines (PQs) and their 4,5-dihydro derivatives (4,5(H)PQ) bearing the (hetero)arylalkylester group at position 3 as ligands at the γ-aminobutyric type A (GABAA) subtype receptor. Continuing the study in this field, we report here the design and synthesis of 3-(hetero)arylpyrazolo[1,5-a]quinazoline and 3-(hetero)aroylpyrazolo[1,5-a]quinazoline 8-methoxy substituted as interesting analogs of the above (hetero)arylalkylester, in which the shortening or the removal of the linker between the 3-(hetero)aryl ring and the PQ was performed. Only compounds that are able to inhibit radioligand binding by more than 80% at 10 µM have been selected for electrophysiological studies on recombinant α1ß2γ2L GABAA receptors. Some compounds show a promising profile. For example, compounds 6a and 6b are able to modulate the GABAAR in an opposite manner, since 6b enhances and 6a reduces the variation of the chlorine current, suggesting that they act as a partial agonist and an inverse partial agonist, respectively. The most potent derivative was 3-(4-methoxyphenylcarbonyl)-8-methoxy-4,5-dihydropyrazolo[1,5-a] quinazoline 11d, which reaches a maximal activity at 1 µM (+54%), and it enhances the chlorine current at ≥0.01 µM. Finally, compound 6g, acting as a null modulator at α1ß2γ2L, shows the ability to antagonize the full agonist diazepam and the potentiation of CGS 9895 on the new α+/ß- 'non-traditional' benzodiazepine site.
Subject(s)
GABA-A Receptor Agonists/chemical synthesis , GABA-A Receptor Antagonists/chemical synthesis , Pyrazoles/chemistry , Quinazolines/chemistry , Receptors, GABA-A/chemistry , Animals , Binding Sites , Cells, Cultured , Chemistry Techniques, Synthetic , GABA-A Receptor Agonists/chemistry , GABA-A Receptor Agonists/pharmacology , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Ligands , Molecular Structure , Protein Binding , Pyrazoles/pharmacology , Quinazolines/pharmacologyABSTRACT
γ-aminobutyric acid-type A (GABAA) receptors mediate fast synaptic inhibition in the central nervous system of mammals. They are modulated via several sites by numerous compounds, which include GABA, benzodiazepines, ethanol, neurosteroids and anaesthetics among others. Due to their potential as targets of novel drugs, a detailed knowledge of their structure-function relationships is needed. Here, we present the model of the α1ß2γ2 subtype GABAA receptor in the APO state and in complex with selected ligands, including agonists, antagonists and allosteric modulators. The model is based on the crystallographic structure of the human ß3 homopentamer GABAA receptor. The complexes were refined using atomistic molecular dynamics simulations. This allowed a broad description of the binding modes and the detection of important interactions in agreement with experimental information. From the best of our knowledge, this is the only model of the α1ß2γ2 GABAA receptor that represents altogether the desensitized state of the channel and comprehensively describes the interactions of ligands of the orthosteric and benzodiazepines binding sites in agreement with the available experimental data. Furthermore, it is able to explain small differences regarding the binding of a variety of chemically divergent ligands. Finally, this new model may pave the way for the design of focused experimental studies that will allow a deeper description of the receptor.
Subject(s)
Benzodiazepines/chemistry , GABA-A Receptor Antagonists/chemistry , Molecular Docking Simulation , Molecular Dynamics Simulation , Receptors, GABA-A/chemistry , Amino Acid Sequence , Benzodiazepines/pharmacology , Binding Sites , Drug Discovery/methods , GABA-A Receptor Antagonists/pharmacology , Hydrogen Bonding , Ligands , Reproducibility of Results , Structure-Activity RelationshipABSTRACT
BACKGROUND: Benzofurans are heterocyclic compounds with neurotropic activity. Some have been developed for the treatment of acute and degenerative neuronal injuries. OBJECTIVE: The study aimed to evaluate the in silico binding of some promising benzofurans on the GABA receptors, and the in vivo neurotropic activity of benzofuran analogues (BZF 6-10) of gamma-aminobutyric acid (GABA) on a seizure model. METHODS: The ligands with the best physicochemical attributes were docked on two GABA receptors (the alpha-1 subunit of GABAA-R and GBR1 subunit of GABAB-R). Selected benzofuran derivatives were synthesized by a multistep procedure and characterized. To examine the neurotropic effects, mice were pretreated with different concentrations of the compounds prior to PTZ- or 4- AP-induced seizures. We assessed acute toxicity, motor behavior, and the effects on seizures. RESULTS: The tested ligands that complied with Lipinski's rule of five were tested in silico with GABAA-R (ΔG = -5.51 to -5.84 kcal/mol) at the allosteric site for benzodiazepines. They bound to a similar cluster of residues as the reference compound (gaboxadol, ΔG = -5.51 kcal/mol). Synthesis was achieved with good overall yields (42-9.7%). Two compounds were selected for biological tests (BZF-7 and rac-BZF-10) on a mouse model of seizures, induced by pentylenetetrazol (PTZ) or 4-aminopyridine (4-AP). PTZ-induced seizures are associated with GABA receptors, and those 4-AP-induced with the blockage of the delayed rectifier-type potassium channel, which promotes the release of the NMDA-sensitive glutamatergic ionotropic receptor and other neurotransmitters. The biological assays demonstrated that BZF-7 and rac-BZF-10 do not protect against seizures. Indeed, BZF-7 increased the number of PTZ-induced seizures and decreased latency time. The 4-AP model apparently showed a potentiation of seizure effects after administration of the BZF-analogues, evidenced by the incidence and severity of the seizures and reduced latency time. CONCLUSION: The results suggest that the test compounds are GABAergic antagonists with stimulatory activity on the CNS.
Subject(s)
Benzofurans/pharmacology , Central Nervous System Stimulants/pharmacology , GABA-A Receptor Antagonists/pharmacology , GABA-B Receptor Antagonists/pharmacology , Animals , Benzofurans/chemical synthesis , Benzofurans/chemistry , Benzofurans/toxicity , Central Nervous System Stimulants/chemical synthesis , Central Nervous System Stimulants/chemistry , Central Nervous System Stimulants/toxicity , GABA-A Receptor Antagonists/chemical synthesis , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/toxicity , GABA-B Receptor Antagonists/chemical synthesis , GABA-B Receptor Antagonists/chemistry , GABA-B Receptor Antagonists/toxicity , Humans , Ligands , Male , Mice , Molecular Docking Simulation , Receptors, GABA-A/chemistry , Receptors, GABA-B/chemistryABSTRACT
Co-administration of solid oral dosage forms with soft food or beverages is commonly used to facilitate administration and to improve compliance in the paediatric and geriatric population and in patient groups with swallowing difficulties. The present case study was conducted to investigate the compatibility, stability and dissolution of Basmisanil administered as granules mixed with different soft food matrices. The data were generated to justify dosing instructions, according which Basmisanil should be sprinkled on or mixed with one tablespoon of soft food to aid swallowing. Different soft food types were selected to cover a broad range of various food components (e.g. fat, protein, carbohydrates, fiber and water) and pH. Active content and degradation products of the active substance were determined after mixing the granules with the semisolid food matrix and after two hours of storage under ambient conditions, respectively. In-vitro dissolution tests of granule/food mixtures were also conducted. Furthermore, the stability of the API polymorph was evaluated. Basmisanil shows good chemical stability when the granules are mixed with soft food and consumed within two hours. No polymorphic conversion (anhydrate to monohydrate) could be detected in the granule/food mixtures after preparation and after storage up to 24â¯h. The in-vitro dissolution of the API from the granules was not adversely affected by the presence of the food matrix. All results were comparable regardless of the tested food matrix. The results do not prohibit the administration of the granules with soft food to the patient.
Subject(s)
Chemistry, Pharmaceutical/methods , Food-Drug Interactions , GABA-A Receptor Antagonists/administration & dosage , Administration, Oral , Drug Liberation , Drug Storage , Food , GABA-A Receptor Antagonists/chemistry , Hydrogen-Ion Concentration , Time FactorsABSTRACT
Photoswitchable neurotransmitter receptors are powerful tools for precise manipulation of neural signaling. However, their applications for slow or long-lasting biological events are constrained by fast thermal relaxation of cis-azobenzene. We address this issue by modifying the ortho positions of azobenzene used in the tethered ligand. In cultured cells and intact brain tissue, conjugating inhibitory neurotransmitter receptors with one of the derivatives, dMPC1, allows bidirectional receptor control with 380 and 500 nm light. Moreover, the receptors can be locked in either an active or an inactive state in darkness after a brief pulse of light. This strategy thus enables both rapid and sustained manipulation of neurotransmission, allowing optogenetic interrogation of neural functions over a broad range of time scales.
Subject(s)
Azo Compounds/metabolism , GABA-A Receptor Antagonists/metabolism , Receptors, GABA-A/metabolism , Synaptic Transmission/drug effects , Animals , Azo Compounds/chemical synthesis , Azo Compounds/chemistry , Azo Compounds/radiation effects , Cells, Cultured , Female , GABA-A Receptor Antagonists/chemical synthesis , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/radiation effects , Humans , Ligands , Male , Mice , Optogenetics/methods , Pregnancy , Stereoisomerism , Ultraviolet RaysABSTRACT
Neurosteroids are powerful modulators of γ-aminobutyric acid (GABA)-A receptors. Ganaxolone (3α-hydroxy-3ß-methyl-5α-pregnan-20-one, GX) and synthetic analogs of the neurosteroid allopregnanolone (AP) are designed to treat epilepsy and related conditions. However, their precise mechanism of action in native neurons remains unclear. Here, we sought to determine the mode of action of GX and its analogs at GABA-A receptors in native hippocampal neurons by analyzing extrasynaptic receptor-mediated tonic currents and synaptic receptor-mediated phasic currents. Concentration-response profiles of GX were determined in two cell types: δ-containing dentate gyrus granule cells (DGGCs) and γ2-containing CA1 pyramidal cells (CA1PCs). GX produced significantly greater potentiation of the GABA-A receptor-activated chloride currents in DGGCs (500%) than CA1PCs (200%). In the absence of GABA, GX evoked 2-fold greater inward currents in DGGCs than CA1PCs, which were 2-fold greater than AP within DGGCs. In hippocampus slices, GX potentiated and directly activated tonic currents in DGGCs. These responses were significantly diminished in DGGCs from δ-subunit knockout (δKO) mice, confirming GX's selectivity for δGABA-A receptors. Like AP, GX potentiation of tonic currents was prevented by protein kinase C inhibition. Furthermore, GX's protection against hippocampus-kindled seizures was significantly diminished in δKO mice. GX analogs exhibited greater potency and efficacy than GX on δGABA-A receptor-mediated tonic inhibition. In summary, these results provide strong evidence that GX and its analogs are preferential allosteric modulators and direct activators of extrasynaptic δGABA-A receptors regulating network inhibition and seizures in the dentate gyrus. Therefore, these findings provide a mechanistic rationale for the clinical use of synthetic neurosteroids in epilepsy and seizure disorders.
Subject(s)
Dentate Gyrus/drug effects , Dentate Gyrus/metabolism , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Pregnanolone/analogs & derivatives , Receptors, GABA-A/metabolism , Allosteric Regulation/drug effects , Animals , Dentate Gyrus/cytology , GABA-A Receptor Antagonists/therapeutic use , Ion Channel Gating/drug effects , Male , Mice , Mice, Inbred C57BL , Neurons/drug effects , Neurons/metabolism , Pregnanolone/chemistry , Pregnanolone/pharmacology , Pregnanolone/therapeutic use , Protein Kinase C/antagonists & inhibitors , Seizures/drug therapy , Synapses/drug effects , Synapses/metabolismABSTRACT
BACKGROUND AND PURPOSE: The pathophysiological role of α6 -subunit-containing GABAA receptors, which are mainly expressed in cerebellar granule cells, remains unclear. Recently, we demonstrated that hispidulin, a flavonoid isolated from a local herb that remitted a patient's intractable motor tics, attenuated methamphetamine-induced hyperlocomotion in mice as a positive allosteric modulator (PAM) of cerebellar α6 GABAA receptors. Here, using hispidulin and a selective α6 GABAA receptor PAM, the pyrazoloquinolinone Compound 6, we revealed an unprecedented role of cerebellar α6 GABAA receptors in disrupted prepulse inhibition of the startle response (PPI), which reflects sensorimotor gating deficits manifested in several neuropsychiatric disorders. EXPERIMENTAL APPROACH: PPI disruptions were induced by methamphetamine and NMDA receptor antagonists in mice. Effects of the tested compounds were measured in Xenopus oocytes expressing recombinant α6 ß3 γ2S GABAA receptors. KEY RESULTS: Hispidulin given i.p. or by bilateral intracerebellar (i.cb.) injection rescued PPI disruptions induced by methamphetamine, ketamine, MK-801 and phencyclidine. Intracerebellar effects of hispidulin were mimicked by Ro15-4513 and loreclezole (two α6 GABAA receptor PAMs), but not by diazepam (an α6 GABAA receptor-inactive benzodiazepine) and were antagonized by furosemide (i.cb.), an α6 GABAA receptor antagonist. Importantly, Compound 6 (i.p.) also rescued methamphetamine-induced PPI disruption, an effect prevented by furosemide (i.cb.). Both hispidulin and Compound 6 potentiated α6 ß3 γ2S GABAA receptor-mediated GABA currents. CONCLUSIONS AND IMPLICATIONS: Positive allosteric modulation of cerebellar α6 GABAA receptors rescued disrupted PPI by attenuating granule cell activity. α6 GABAA receptor-selective PAMs are potential medicines for treating sensorimotor gating deficits in neuropsychiatric disorders. A mechanistic hypothesis is based on evidence for cerebellar contributions to cognitive functioning including sensorimotor gating.
Subject(s)
Flavones/pharmacology , GABA-A Receptor Antagonists/pharmacology , Mental Disorders/drug therapy , Prepulse Inhibition/drug effects , Receptors, GABA-A/metabolism , Animals , Flavones/chemistry , GABA-A Receptor Antagonists/chemistry , Male , Mental Disorders/metabolism , Mice , Mice, Inbred ICRABSTRACT
GABAA receptors are ligand-gated anion channels that form pentameric arrangements of various subunits. Positive allosteric modulators of GABAA receptors have been reported as being isolated either from plants or synthesized analogs of known GABAA receptor targeting drugs. Recently, we identified monoterpenes, e.g. myrtenol as a positive allosteric modulator at α1ß2 GABAA receptors. Here, along with pharmacophore-based virtual screening studies, we demonstrate that scaffold modifications of myrtenol resulted in the loss of modulatory activity. Two independent approaches, fluorescence-based compound analysis and electrophysiological recordings in whole-cell configurations were used for analysis of transfected cells. C-atoms 1 and 2 of the myrtenol backbone were identified as crucial to preserve positive allosteric potential. A modification at C-atom 2 and lack of the hydroxyl group at C-atom 1 exhibited significantly reduced GABAergic currents at α1ß2, α1ß2γ, α2ß3, α2ß3γ and α4ß3δ receptors. This effect was independent of the γ2 subunit. A sub-screen with side chain length and volume differences at the C-atom 1 identified two compounds that inhibited GABAergic responses but without receptor subtype specificity. Our combined approach of pharmacophore-based virtual screening and functional readouts reveals that side chain modifications of the bridged six-membered ring structure of myrtenol are crucial for its modulatory potential at GABAA receptors.